~~<i id='C3E75768B8'><strike id='C3E75768B8'><tt id='C3E75768B8'><pre id='C3E75768B8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：comprehensive 2025-09-05 13:47:00 - browse：545

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Time to name cancers by genetics, not organ of origin, expert says

hotspot

entertainment

Wikipedia

leisure time

Wikipedia

focus

AdobeBiotechandlifesciencesinvestorscontinuetodrawinnewfundsevenasthebiotechstockindexesreachnewlows

WSS

FDA drug safety: Singulair case shows systemic surveillance flaws

Novo Nordisk to expand supply of Wegovy for U.S. patients

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Time to name cancers by genetics, not organ of origin, expert says

Congressmen charge Covid hearing ‘could have been an email’

All of Us, NIH's precision medicine initiative, gets a big boost

hotspot

explore

hotspot

How one medical school became remarkably diverse

New Ultima Genomics DNA sequencer can read genome for $100

As demand for Covid shots wanes, Moderna seeks its next success

New Ultima Genomics DNA sequencer can read genome for $100

How one medical school became remarkably diverse

Kidney transplant patients stopped immunosuppressants in trial

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Vertigo drug brings hope for rare neuron disorder, Niemann

Novavax promises a turnaround & Lilly roils the obesity market

Explaining an after

entertainment

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Apple Vision Pro: A first look at health apps on the new VR headset

What is microchimerism and how does it affect maternal health?

After Sarepta trial failure, Duchenne families brace for more debate

Brain injuries and the importance of a second opinion

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Wikipedia

leisure time

Wikipedia

focus